股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金威醫療集團有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08143 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 22,000,000,000 | HKD | | 0.05 HKD | | 1,100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 22,000,000,000 | HKD | | 0.05 HKD | | 1,100,000,000 | | 2. 股份分類 | 優先股 | 股份 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金威醫療集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08143 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 22,000,000,000 | HKD | | 0.05 | HKD | | 1,100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 22,000,000,000 | HKD | | 0.05 | HKD | | 1,100,000,000 | | ...

(Stock Code 股份代號 ： 8143) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） NOTIFICATION LETTER 通知信函 29 December 2025 Dear Non-registered Holder(s) (Note 1) , Good Fellow Healthcare Holdings Limited (the "Company") Notification of Publication of Interim Report 2025/2026 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication are available on the Company's website at www.gf-healthcare.com and the website of The Stock Exchange o ...

Note: (Stock Code 股份代號 ： 8143) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） NOTIFICATION LETTER 通知信函 29 December 2025 Dear Registered Shareholders, Good Fellow Healthcare Holdings Limited (the "Company") Notification of Publication of Interim Report 2025/2026 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication are now available on the Company's website at www.gf-healthcare.com and the website of The Stock Exchange of ...

香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）之特色 GEM為投資風險較其他於聯交所上市之公司為高之中小型公司提供上市之市場。有 意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出 投資決定。 由於GEM上市之公司通常為中小型公司，在GEM買賣之證券可能會較在聯交所主板 買賣之證券承受較大之市場波動風險，同時無法保證在GEM買賣之證券會有高流通 量之市場。 | | | 截至九月三十日 | | | --- | --- | --- | --- | | | | 止六個月 | | | | | 二零二五年 | 二零二四年 | | | | 千港元 | 千港元 | | | 附註 | （未經審核） | （未經審核） | | 收益 | 4及5 | 10,500 | 10,435 | | 銷售成本 | | (2,166) | (2,254) | | 毛利 | | 8,334 | 8,181 | | 其他收益 | | 280 | 61 | | 出售附屬公司之收益 | | – | 10,458 | | 銷售及分銷開支 | | (2,582) | (1,549) | | 行政開支 | | (8,722 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金威醫療集團有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08143 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 22,000,000,000 | HKD | | 0.05 | HKD | | 1,100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 22,000,000,000 | HKD | | 0.05 | HKD | | 1,100,000,000 | ...

Group 1 - The company, Kingway Medical (08143), reported a revenue of HKD 10.5 million for the six months ending September 30, 2025, representing a year-on-year increase of 0.62% [1] - The company experienced a loss attributable to shareholders of HKD 2.671 million, marking a shift from profit to loss compared to the previous year [1] - The loss per share was reported at HKD 0.237 [1]

Financial Performance - For the six months ended September 30, 2025, the group recorded total revenue of approximately HKD 10,500,000, compared to HKD 10,435,000 for the same period in 2024, indicating a stable revenue level [4]. - The gross profit margin for the six months ended September 30, 2025, was approximately 79.37%, an increase from 78.40% in the same period of 2024 [4]. - The group reported a loss attributable to owners of the company of approximately HKD 2,671,000 for the six months ended September 30, 2025, compared to a profit of HKD 7,602,000 in the same period of 2024, primarily due to the absence of one-time gains from the sale of subsidiaries [4]. - The company reported a basic and diluted loss per share of HKD 0.237 for the six months ended September 30, 2025, compared to earnings per share of HKD 1.349 in the same period of 2024 [6]. - The company reported a net profit of HKD 7,602,000 for the six months ended September 30, 2025, compared to a net loss of HKD 2,671,000 for the same period in 2024 [9]. - The total comprehensive income for the period was HKD 7,265,000 after accounting for total expenses [9]. - The company incurred a loss attributable to owners of approximately HKD 2,671,000 for the six months ended September 30, 2025, compared to a profit of HKD 7,602,000 for the same period in 2024, marking a significant decline [30]. Assets and Liabilities - Total assets as of September 30, 2025, amounted to HKD 20,706,000, compared to HKD 9,832,000 as of March 31, 2025, reflecting significant growth in asset value [7][8]. - Current assets increased to HKD 19,183,000 as of September 30, 2025, from HKD 8,559,000 as of March 31, 2025, indicating improved liquidity [7]. - The company's equity attributable to owners increased to HKD 19,076,000 as of September 30, 2025, compared to a negative equity of HKD 6,509,000 as of March 31, 2025 [7]. - Current liabilities decreased significantly to HKD 1,868,000 as of September 30, 2025, from HKD 16,587,000 as of March 31, 2025, improving the company's financial position [8]. - The current ratio as of September 30, 2025, was approximately 9.26, a substantial increase from 0.52 as of March 31, 2025 [38]. - The debt-to-equity ratio was not applicable as of September 30, 2025, compared to 99.19% as of March 31, 2025 [39]. Cash Flow - Cash and cash equivalents at the end of the period rose to HKD 7,519,000, up from HKD 1,630,000 at the end of September 2024 [11]. - The company experienced a cash outflow of HKD 14,463,000 from operating activities for the six months ended September 30, 2025, compared to a cash inflow of HKD 476,000 in the previous year [11]. - The company reported a net cash inflow from the rights issue amounting to approximately HKD 26,700,000 [26]. Expenses - Sales and distribution expenses increased by approximately 66.69% to HKD 2,582,000 for the current period, up from HKD 1,549,000 in the previous year, primarily due to higher spending on online promotion and marketing services [30]. - Administrative expenses decreased by approximately 7.79% to HKD 8,722,000 for the current period, compared to HKD 9,459,000 in the previous year, indicating improved cost management [30]. - The total employee cost for the review period was approximately HKD 4,154,000, down from HKD 6,699,000 in the previous year [47]. Dividends - The board of directors did not recommend the distribution of dividends for the six months ended September 30, 2025, consistent with the previous year [4]. - The company did not declare any dividends for the six months ended September 30, 2025, consistent with the previous year [27]. - The company did not recommend any dividend for the six months ended September 30, 2025, consistent with the previous year [44]. Corporate Governance - The company has complied with the corporate governance code as per GEM listing rules during the review period [63]. - The audit committee, consisting of independent non-executive directors, has reviewed the unaudited condensed consolidated results, ensuring compliance with applicable accounting standards and GEM listing rules [67]. - The company has established a remuneration committee responsible for determining the specific remuneration packages of all executive directors, including benefits and compensation [64]. - The company has a nomination and corporate governance committee that reviews the board's structure and recommends suitable candidates for board membership [65]. Strategic Developments - The company continues to focus on providing comprehensive hospital services in China, with all revenues generated from this segment [18]. - The company is strategically optimizing regional resource allocation to focus on markets with clearer long-term growth attributes, particularly in advanced medical procedures and specialized treatments [34]. - The company has submitted an application for a tertiary specialized hospital in Hainan, significantly upgrading from the previously planned secondary classification, reflecting its commitment to meet increasing clinical and comprehensive medical service demands in China [34]. - The company has signed a five-year lease for a property of 13,800 square meters in Hainan for the operation of the Hainan hospital, with an additional two-year lease for a 340 square meter medical facility [36]. - The expected issuance of the medical institution license for the Hainan hospital is anticipated in December 2025, with the operational license expected in the first half of 2026 [36]. - The company aims to leverage favorable policies and strategic advantages in Hainan to capture significant growth potential in the local healthcare market [35]. - The company is open to exploring suitable opportunities in Beijing and other regions if market conditions become more favorable, despite the ongoing contraction of its Beijing business [33]. - The company is adjusting its business deployment in response to structural changes in patient demand and service preferences in the Chinese healthcare market [33]. - The company has appointed Mr. Wang Haitao as the CEO of the Hainan hospital, bringing extensive experience in hospital management and healthcare investment [36]. Share Capital - The company issued shares during the rights issue, resulting in an increase of HKD 28,183,000 in equity [9]. - The company issued 563,649,988 new shares through a rights issue at a subscription price of HKD 0.05 per share, increasing the total issued share capital to 1,146,999,976 shares [26]. - The weighted average number of ordinary shares for calculating basic loss per share was approximately 1,127,299,976 shares for the current period, compared to 563,649,988 shares for the previous year [23]. - The company has not established any preferential rights for existing shareholders regarding the issuance of new shares [61]. - The company has not granted any stock options that remain unexercised as of the six months ending September 30, 2025 [58]. Other Information - The company has not applied any new accounting standards that have been issued but not yet effective, which would have a significant impact on its financial statements [15]. - There were no significant acquisitions or disposals of subsidiaries or associates during the review period [48]. - The company had no contingent liabilities or significant litigation as of September 30, 2025 [42]. - There were no major capital commitments as of September 30, 2025, remaining unchanged from March 31, 2025 [40]. - There were no purchases, sales, or redemptions of the company's listed securities by the company or any of its subsidiaries during the six months ending September 30, 2025 [59]. - As of September 30, 2025, there are no interests held by directors or their associates in any business that competes directly or indirectly with the group [60].

Core Viewpoint - Kingway Medical (08143) anticipates a loss of approximately HKD 2.7 million for the six months ending September 30, 2025, compared to a profit of about HKD 7.6 million for the corresponding period ending September 30, 2024 [1] Financial Performance - The company expects to achieve operational revenue of approximately HKD 10.5 million for the current period, which is similar to the revenue of about HKD 10.4 million for the corresponding period [1] - The anticipated shift from profit to loss is primarily attributed to the absence of a one-time gain of approximately HKD 10.5 million recognized from the sale of a subsidiary in the corresponding period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 由於本公司仍在落實本集團於本期間之未經審核綜合財務業績（「中期業績」），本公告 所載資料僅為董事會基於對本集團之未經審核綜合管理賬目之初步評估及現時可獲得 資料作出之初步評估，尚未經董事會轄下之審核委員會或本公司核數師落實或審閱及 可因進一步審閱作出更改及調整。 中期業績或會有別於本公告所披露者。股東及潛在投資者務請細閱定於二零二五年 十一月刊發之中期業績。 股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 （股份代號 ： 8143） （於開曼群島註冊成立之有限公司） 盈利警告 本公告乃由金威醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司GEM證券上市規則（「GEM上市規則」）第17.10條及香港法例第 571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見GEM上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東 ...